Next Article in Journal
Renal Morphology in Coronavirus Disease: A Literature Review
Previous Article in Journal
Clinical Profile and Length of Hospital Stay in a Sample of Psychogeriatric Patients Referred to Consultation Liaison Psychiatric Unit
Article

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

1
Department of Infectious Diseases, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
2
Department of Gynecology, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
3
“Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Academic Editor: Won Suk Choi
Medicina 2021, 57(3), 257; https://doi.org/10.3390/medicina57030257
Received: 21 February 2021 / Revised: 28 February 2021 / Accepted: 2 March 2021 / Published: 11 March 2021
Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients. View Full-Text
Keywords: convalescent plasma; COVID-19; critically ill; transfusion; SARS CoV-2 convalescent plasma; COVID-19; critically ill; transfusion; SARS CoV-2
Show Figures

Figure 1

MDPI and ACS Style

Tirnea, L.; Bratosin, F.; Vidican, I.; Cerbu, B.; Turaiche, M.; Timircan, M.; Margan, M.-M.; Marincu, I. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients. Medicina 2021, 57, 257. https://doi.org/10.3390/medicina57030257

AMA Style

Tirnea L, Bratosin F, Vidican I, Cerbu B, Turaiche M, Timircan M, Margan M-M, Marincu I. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients. Medicina. 2021; 57(3):257. https://doi.org/10.3390/medicina57030257

Chicago/Turabian Style

Tirnea, Livius, Felix Bratosin, Iulia Vidican, Bianca Cerbu, Mirela Turaiche, Madalina Timircan, Madalin-Marius Margan, and Iosif Marincu. 2021. "The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients" Medicina 57, no. 3: 257. https://doi.org/10.3390/medicina57030257

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop